Onward Medical

Phase A — Understand the business

Lens 1 · Company Overview

ONWARD Medical is a neurotechnology company commercialising "ARC Therapy" — targeted, programmed electrical stimulation of the spinal cord to restore movement and autonomic function in people with spinal cord injury (SCI) . It is a spin-out of **EPFL (Lausanne)** founded in December 2014 by neurosurgeon **Prof. Jocelyne Bloch**, neuroscientist **Prof. Grégoire Courtine**, and **Sjaak Deckers** . HQ is Eindhoven, Netherlands, with a science & engineering centre in Switzerland (tied to the.NeuroRestore lab at EPFL/CHUV) and a US commercial office in Boston ``.

The product architecture is two delivery modes of the same core IP:

• ARC-EX — external / non-invasive. An external stimulator + wireless programmer driving electrodes placed transcutaneously on the back of the neck. This is the only product generating revenue today. FDA De Novo market authorisation December 2024; CE Mark September 2025; FDA 510(k) expanded indication for home use November 2025 (C2–C8 incomplete SCI, to improve hand strength and sensation) . It is sold to rehab clinics and, since late 2025, into the home (including Veterans Affairs placements) .
• ARC-IM — implantable. A surgically implanted spinal stimulator targeting indications ARC-EX cannot — first up is blood-pressure (hemodynamic) instability after SCI (the Empower BP pivotal study), with movement, Parkinson's, and BCI-paired programs behind it. Investigational; no revenue; commercialisation guided to H2 2028 ``.
• ARC-BCI — brain-computer interface. ARC-IM stimulation driven by a brain implant + AI decoder to restore thought-driven arm/hand/leg movement. First-in-human "digital bridge" work with.NeuroRestore; investigational, earliest-stage ``.

Business model: capital-equipment + consumables medtech. ARC-EX is a hardware system sold per-clinic / per-patient with consumable electrode components and a software programmer — recurring revenue is thin today and the install base is the leading indicator (clinics → home patients). The long-run model is the implantable razor-and-blade (ARC-IM device + programming + follow-up), which does not exist commercially yet.

Customers: US rehabilitation clinics (80+ at end-2025, 100+ across US+EU by Q1 2026), the VA system, and — for ARC-IM — academic trial sites (Craig Hospital Denver, ~12 US sites activated) . The Christopher & Dana Reeve Foundation and Shepherd Center are clinical/advocacy partners . Suppliers/partners: Ottobock (German prosthetics/orthotics giant, now ONWARD's largest shareholder — a strategic-distribution tell) and the .NeuroRestore / EPFL research engine that feeds the pipeline.

Lens 2 · Supply Chain

ARC-EX is a relatively simple external electronic device, so the "supply chain" is less a commodity-input chain (as in semis/energy) than a medtech contract-manufacturing + clinical-channel chain. Named stakeholders along it:

• Upstream IP / R&D: .NeuroRestore (Defitech Center for Interventional Neurotherapies, jointly run by EPFL, CHUV/Lausanne University Hospital, University of Lausanne) — the lab led by founders Courtine & Bloch that generates the science (e.g. the Nature 2022 walking-neuron paper, the Nature Medicine 2025 hemodynamic-implant paper) ``. This is a genuine single-source dependency for the pipeline — the moat and the chokepoint are the same node.
• Component supply / manufacturing: external stimulator electronics, electrode arrays, and the implantable pulse generator (for ARC-IM) are built via medtech CDMO/component suppliers. Specific contract manufacturers are n/a in public materials; ONWARD has not named them in the press releases reviewed.
• The company: ONWARD (Eindhoven design/regulatory + Swiss engineering) integrates, holds the FDA/CE authorisations, and owns the clinical evidence.
• Strategic distribution / channel: Ottobock — the world's largest orthotics/prosthetics company and ONWARD's largest shareholder since Oct 2024 — is the obvious channel partner into rehab/mobility, though a formal global distribution agreement is n/a as a signed contract.
• Downstream: US rehab clinics → patients (clinic + home); the VA; European clinics post-CE (e.g. Neurokinex, first UK centre) ``.

Chokepoints: (1) the science pipeline is single-sourced to one Swiss lab and two founders; (2) reimbursement is the real chain bottleneck, not silicon — without a CMS/payer pathway the clinic and home channel is self-pay-constrained (see Lens 3 / Lens 13). Names-or-it-didn't-happen caveat: the manufacturing tier is genuinely undisclosed and I will not invent CDMO names.

Lens 3 · Competitive Advantages (moats)

ONWARD's moat is regulatory-first-mover + scientific provenance + IP, and it is real but narrow:

1. Regulatory first-mover. ARC-EX is "the first and only FDA-authorised technology indicated to improve hand strength and sensation in chronic SCI" ``. A De Novo grant creates a new device classification — followers must either ride ARC-EX's predicate (validating the category) or run their own De Novo/PMA. That is a multi-year, multi-trial barrier. Durable for now.
2. Clinical evidence. The Up-LIFT pivotal trial (65 chronic-tetraplegia participants, 14 SCI centres across US/EU/Canada) hit all primary and secondary safety + efficacy endpoints, published in Nature Medicine (May 2024): 90% improved upper-limb strength or function, 87% reported QoL improvement ``. Top-tier-journal evidence is a marketing and payer moat competitors can't fake.
3. Scientific provenance / talent. Courtine + Bloch are among the most cited names in neurorestoration (Queen Elizabeth Prize for Engineering nominees/winners); the.NeuroRestore pipeline is a multi-decade lead in spinal neuromodulation ``. This is the strongest moat — it's a people-and-data asset rivals can't acquire.
4. IP estate. Patent portfolio around targeted epidural/transcutaneous stimulation and BCI-paired stimulation. Specific patent counts/expiries are n/a (the research-layer patents/ dir is empty).

Bargaining power: weak today. As a sub-€6M-revenue company selling into rehab clinics with no established reimbursement code, ONWARD needs the clinics and payers far more than they need it. Power inverts only if/when (a) reimbursement lands and (b) ARC-IM proves an implantable franchise. Ottobock as largest shareholder is a partial offset — a strategic with global mobility distribution has skin in the game.

Verdict on moat: a defensible category-creation moat (regulatory label + Nature-grade data + founder science) sitting on top of no commercial moat yet (no reimbursement, trivial install base, single-product revenue). The moat protects the future, not the present P&L.

Lens 4 · Segments

No segment-level breakout is disclosed (the research-layer segments.csv is empty; the company reports one operating segment). What is sourceable:

• By product (FY2025): Total revenue €5.4M of which product revenue €3.7M (mainly ARC-EX); the €1.7M balance is non-product — i.e. collaboration/grant/other income . By Q1 2026, total revenue **€2.0M**, ARC-EX product **€1.3M** .
• By geography: US-led. ARC-EX commercial traction is concentrated in the US (80+ clinics end-2025); Europe opened only after the Sep-2025 CE Mark, so EU revenue is nascent ``.
• Trend: accelerating off a tiny base. Revenue €1.7M (2024) → €5.4M (2025) ≈ +218% YoY ; Q1 2026 €2.0M annualises to ~€8M , and Q1 product €1.3M ≈ 70 systems implies ~€18.6k ASP per ARC-EX system — directionally consistent with FY2025's €3.7M product / 117 systems ≈ **€31.6k/system**, the gap reflecting consumables-vs-system mix and is worth watching (is ASP falling, or is the mix shifting to lower-priced home units?).

The honest read: there is no meaningful segmentation because there is essentially one product line and one geography that matters. Diversification is a pipeline promise, not a current fact.

---

Phase B — Measure performance (clinical-stage overlay)

Lens 5 → Pipeline by phase (swapped for clinical-stage; the asset table IS the company)

**Probability-of-success (PoS) — , directional, not sourced from a model:** ARC-EX is *approved* so commercial-execution risk, not technical (PoS≈1 on the science). Empower BP carries the classic pivotal binary — call it **~50–65%** given the strong mechanistic Nature Medicine support . BCI is a low-single-digit-to-call optionality program — genuinely exciting, genuinely a decade-class effort.

The asset table is the company: an approved-but-tiny ARC-EX present, an ARC-IM hemodynamic pivotal that is the real 2027–28 catalyst, and a BCI moonshot that drives the narrative (and arguably the multiple) far more than the near-term numbers justify.

Lens 6 · Earnings Calls / management messaging (sentiment trend)

No transcripts on the shelf (transcripts/ empty); reading off the press-release commentary and call summaries ``:

• Consistent drumbeat: "world-first," "resounding success" of ARC-EX launch, "rapid traction," "strong US commercial performance." CEO Dave Marver, Q1 2026: "Launch of ARC-EX continues to be a resounding success, with strong initial home-use sales in the US and rapid traction…" ``.
• Tone shift over the last ~4 reports: FY2024 → Q1 2025 → Q3 2025 → FY2025 → Q1 2026 shows a clear pivot from "we got approved" to "we are commercialising," and increasingly to "ARC-IM/Empower BP is the next leg." The capital raises (Oct 2025 €50.9M, Apr 2026 €40M+) are framed as funding both ARC-EX commercialisation and ARC-IM development — management is explicitly telling you the implantable is where the value is.
• What they emphasise: system counts, clinic counts, regulatory milestones, runway extension. What is conspicuously under-discussed: reimbursement / coverage codes and a clear path-to-profitability date. That asymmetry is the tell — they sell the install-base and pipeline momentum, and stay quiet on the unit economics and the cash-flow horizon.

Lens 7 → Catalyst calendar + mechanism comps (swapped for clinical-stage)

Catalyst calendar (what de-risks or kills the thesis, and when):

Mechanism comps (by what they do, not by P/E — the company has no E):

• Implanted SCS incumbents — Medtronic, Abbott, Boston Scientific: huge installed bases but indicated for chronic pain, not SCI functional recovery; ARC-EX/ARC-IM is a different indication, so they are adjacent not head-to-head — but they own the surgical channel and could fast-follow ``.
• Exoskeletons — Ekso Bionics, Lifeward (ex-ReWalk): the prior "restore mobility after SCI" category; both are small-cap, reimbursement-challenged, and a cautionary comp for ONWARD's own coverage path ``.
• BCI — Neuralink (private), Synchron (private), Blackrock Neurotech, Precision Neuroscience: ONWARD's ARC-BCI competes here on the movement-restoration use case, but ONWARD's edge is pairing BCI with its own spinal stimulator (the "digital bridge"). All are pre-commercial `.
• EV/Sales / P/E peer multiples: n/a. On €5.4M revenue and no earnings, conventional multiples are meaningless and I will not manufacture them. This is an rNPV/runway story (Lens 11), not a comps story.

Lens 8 · Stock-Price Catalysts (what actually moves the tape)

• All-time high €13.28 (Oct 2021), all-time low €1.85 (Jan 2024) — an ~86% peak-to-trough drawdown ``. The de-rating tracks the broader 2021→2023 clinical-medtech/SPAC-era unwind plus serial dilution.
• −28% over the trailing year to ~€2.82–2.83 ``.
• What the tape reacts to: (1) regulatory milestones — the Dec-2024 FDA De Novo and Nov-2025 home-use clearance are the cleanest positive catalysts; (2) capital raises — repeated equity placements (€40.6M EQT-led 2026; €50.9M Oct-2025; €40M+ Apr-2026) are dilutive overhangs that cap rallies; (3) clinical/scientific readouts — Nature Medicine publications and BCI implant news drive narrative spikes. The pattern: science/regulatory good news pops it, the next raise gives it back. The market is trading the gap between a thrilling pipeline and a relentless cash burn.

Sourcing conflict flagged: one source lists an "IPO date 24 Sep 2024," but the all-time high of €13.28 dates to Oct 2021 and other sources cite a 2021 Euronext listing. The Euronext IPO was October 2021; the "Sep 2024" stamp is almost certainly an OTCQX ADR (ONWRY) start date mislabelled as the IPO. Treating 2021 as the listing date. ``

---

Phase C — Judge people & books (+ Science & exclusivity)

Lens 9 · Management

• CEO — Dave Marver (since July 2020). 25+ yrs medtech; ~15 years at Medtronic (VP Sales/Marketing/Strategy/BD, US + Europe), then CEO of NASDAQ-listed Cardiac Science Corp, then co-founded two start-ups. Duke BA (Psychology), UCLA MBA ``. Read: a credible commercial medtech operator (Medtronic pedigree is exactly the right channel/regulatory DNA for scaling ARC-EX) rather than a scientist-founder. The right archetype for the commercialisation phase the company is entering.
• CSO / co-founder — Prof. Grégoire Courtine, and co-founder neurosurgeon Prof. Jocelyne Bloch (leads the surgical/clinical side via.NeuroRestore). World-class scientific founders, still actively driving the pipeline from EPFL/CHUV — the single most valuable asset on the cap table. ``
• Tenure & skin in the game: founders retain scientific leadership; insider ownership %, board comp, and an insider-transactions.csv are n/a (research layer empty). Ottobock is the largest shareholder (from a €22.5M Oct-2024 investment), and EQT Life Sciences is a long-standing holder (since 2016) that just put in €25M (Apr 2026) — strategic + crossover-style backing is a quality signal ``.
• Capital-allocation history: this is a cash-consuming clinical company, so "capital allocation" = how well it spends raised equity. Allocation of the Apr-2026 round was disclosed: 40% ARC-IM development, 30% ARC-EX commercialisation, 20% quality/admin, 5% working capital, 5% financing `` — i.e. the company is betting the larger share on the implantable, consistent with where it says the value is. ROE/ROIC are deeply negative by construction (€41.8M loss); not a meaningful lens pre-scale.
• Red flags (management): none of the classic governance red flags (related-party, promotional-CEO, accounting games) surfaced in public sources — but the serial dilution is the de-facto capital-allocation reality, and the persistent under-emphasis on reimbursement in IR messaging is a soft flag (see Lens 13). Founder/operator split is healthy.

Lens 10 · Forensic Red Flags (re-pointed to clinical-stage: trial integrity, going-concern, dilution)

No SEC filings exist to forensically pick apart (no CIK), so this is a going-concern + dilution + trial-integrity read off the public numbers, all ``:

• Cash-burn vs. cash: FY2025 net loss €41.8M ; year-end-2025 cash **€68.1M**; Q1-2026 cash **€53.4M** → **~€14.7M cash burned in Q1 alone** , i.e. a ~€50–60M annualised burn . The Apr-2026 €40M+ raise pushes guided runway to **~Q1 2028** — meaning another raise is near-certain before profitability. This is the dominant financial risk: not fraud, but dilution as a structural feature.
• Revenue recognition / quality: revenue is tiny and product-based (hardware + consumables); the €1.7M FY2025 non-product line (grants/collaboration) is worth watching as it can flatter "total revenue" headlines — always read product revenue (€3.7M FY2025 / €1.3M Q1-2026), not total. ``
• Gross margin: product gross margin ~72% (FY2025) `` — genuinely healthy hardware economics if volume scales; the problem is OpEx (€45.3M FY2025, M&A/market-access more than doubled to €8.1M), not COGS.
• Going concern: no explicit going-concern flag found in public sources, consistent with the freshly-topped-up balance sheet — but the runway is finite and disclosed. ``
• Trial integrity: Up-LIFT was a 65-patient, 14-site, peer-reviewed (Nature Medicine) pivotal that hit all endpoints — a high-integrity dataset, not a press-release-only claim ``. Empower BP design (interim early 2027) is the next integrity test.

Regulatory findings (required sub-section).

• SEC LR / AAER: None possible — ONWARD has no CIK and is not an SEC filer; regulatory/regulatory-findings.md (generated 2026-06-30 via SEC EDGAR EFTS) returns 0 findings and notes the no-CIK limitation ``.
• Non-SEC enforcement (web search): a search for "Onward Medical" (FTC OR DOJ OR FDA OR CFPB OR consent-decree OR settlement OR fine OR penalty) enforcement surfaced no material enforcement actions, consent decrees, fines, or penalties. FDA appearances are authorisations (De Novo, 510(k)), i.e. the good kind of FDA contact, not enforcement ``.
• Item 3 / Legal Proceedings: n/a — no 10-K exists (not an SEC filer). Any litigation would surface in the Dutch annual report; none material found in public sources.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (no CIK → 0 findings) and web search across FDA/FTC/DOJ as of 2026-06-30. FDA interactions are device authorisations, not enforcement.

Science & exclusivity (clinical-overlay add to Phase C)

• Mechanism validation: strong. ARC-EX's efficacy is Nature-Medicine-published (Up-LIFT); the ARC-IM hemodynamic mechanism has a 2025 Nature Medicine implant paper from.NeuroRestore ``. This is not hand-wavy preclinical hope — the core mechanism is peer-reviewed in the top journal in the field.
• KOL / founder credibility: Courtine & Bloch are field-defining; the.NeuroRestore lab is arguably the leading academic centre in spinal neuromodulation. Exclusivity flows from this relationship as much as from patents.
• IP estate & cliff: patent portfolio around targeted stimulation + BCI-paired stimulation; specific patent numbers / expiry dates n/a (research-layer patents/ empty). A genuine open item.
• Reimbursement / payer path: the weakest link. ARC-EX is FDA-cleared and CE-marked but CMS/Medicare and commercial-payer coverage is n/a / not yet established in public materials — the company sells largely without a settled reimbursement code, which structurally caps the addressable commercial demand until coverage lands. This is the gating commercial variable.

---

Phase D — Project & stress-test

Lens 11 → rNPV + runway-to-catalyst (swapped for clinical-stage)

Do not expect an EPS line — this company has no E and won't for years. The right frame is rNPV of the assets + the runway question.

Runway-to-catalyst (the question that matters most):

• Cash Q1-2026: €53.4M; + Apr-2026 raise ~€40M ≈ ~€90M+ pro-forma; guided runway into Q1 2028 ``.
• Next value-inflection catalyst: Empower BP interim analysis, early 2027 ``.
• So: yes — current cash reaches the next major de-risking catalyst (early-2027 interim) with margin, but NOT through ARC-IM commercialisation (H2 2028). A further raise is required to bridge from the 2027 interim to 2028 commercialisation — dilution is mathematically baked in. ``

rNPV sketch (illustrative, every input `` — not a sourced model):

• ARC-EX (approved): US chronic-incomplete-SCI addressable population is a subset of the ~300k US SCI prevalence ; assume tens of thousands of addressable chronic-tetraplegia patients. At an ~€20–30k system ASP and ~72% product margin, even a few thousand systems = a €50–100M+ revenue franchise — but that is gated entirely on reimbursement + adoption pace. PoS≈high (already approved); commercial-realisation risk is the discount.
• ARC-IM Empower BP: the lead value driver; rNPV = peak-sales × PoS (~50–65% ``) × discount. Hemodynamic instability is a serious, underserved post-SCI problem with no good therapy — pricing power on an implant is high. Bulk of the analyst-target value sits here and in optionality, not in ARC-EX.
• ARC-BCI / Parkinson's: call it option value — real but un-modelable; it is doing disproportionate work in the narrative and arguably the multiple.

Reconciling to the market: share ~€2.82, ~69.5M shares → market cap ~€196M (one source shows $234M on FX/date differences — flagged, not merged). Analyst consensus is "Strong Buy," 5/5 buy, average 12-month target ~€9.44–9.50 — i.e. ~+235% upside to the target ``. That gap is the entire investment debate: the Street is pricing the ARC-IM/BCI franchise as a near-foregone conclusion; the tape is pricing a serial-diluting pre-revenue medtech. Both can't be right.

Brier forecast — NOT logged (per --watchlist rule: skip forecast.ts create in the loop; no genuine committed base case here). The forecast to log on a future committed pass would be a binary: "ARC-IM Empower BP interim (early 2027) reports a clinically meaningful, statistically significant BP-regulation benefit," with a base-case p ≈ 0.55 ``.

Lens 12 · Bull vs Bear

Bull case. ONWARD owns a category: the world's first and only FDA-authorised non-invasive SCI functional-recovery therapy, backed by Nature-Medicine-grade evidence and the leading academic lab in the field. ARC-EX is ramping fast (€1.7M→€5.4M revenue, 117 systems, 100+ clinics, home + VA), with ~72% product margins that scale beautifully once volume and reimbursement arrive. Behind it sits a genuine franchise optionality — ARC-IM for blood-pressure instability (a serious unmet need, pivotal interim early-2027, launch H2-2028), plus Parkinson's and a BCI "digital bridge" that puts ONWARD in the same conversation as Neuralink/Synchron but with an approved spinal-stimulation platform already in market. Strategic backing (Ottobock as #1 holder, EQT Life Sciences re-upping €25M) signals smart-money conviction. If reimbursement lands and Empower BP hits, the €9+ targets are defensible and today's ~€196M cap looks like an option mispriced at intrinsic.

Bear case (permanent-impairment risks). (1) Reimbursement never properly materialises — like the exoskeleton names (Ekso, Lifeward), ARC-EX stays a self-pay / grant-funded niche, capping revenue far below the bull TAM and stranding the commercial thesis. (2) Dilution grinds shareholders down — ~€58M annual burn, runway only to ~Q1 2028, and a guided H2-2028 ARC-IM launch beyond the cash horizon means at least one more dilutive raise (likely two) before profitability; at a depressed ~€2.8 share price, each raise is brutally dilutive. (3) Empower BP disappoints or slips — the implantable franchise is the bulk of the target value; a failed/ambiguous early-2027 interim or a multi-year delay collapses the bull rNPV and removes the reason to own it over ARC-EX alone.

Pre-mortem (18 months out, thesis broke): It's end-2027. The Empower BP interim came in ambiguous (underpowered or mixed), ARC-EX revenue plateaued around €10–15M because Medicare still hasn't issued a coverage decision, and the company has done another deeply dilutive raise at a lower price. Share count is up ~30%+, the BCI program is still "investigational," and the stock is back near its €1.85 all-time low. The bull thesis required two things to go right (reimbursement and the pivotal); only one did.

Are the multiples too high? There is no earnings multiple. On price-to-sales the stock is ~36× FY2025 revenue — only justifiable if you fully credit the ARC-IM/BCI franchise. The €9.50 analyst target implies a **~€660M cap**, i.e. ~120× current sales — that is a pure pipeline/rNPV valuation, not an operating one. Expectations baked into the Street target are extremely high; expectations baked into the tape are low.

Contrarian view (what the market is refusing to see): The consensus among analysts (Strong Buy, +235% target) and the price action (−28% YoY, near multi-year lows, serial dilution) are flatly contradicting each other — and the tape is usually right about dilutive pre-revenue medtech. The thing the bulls refuse to see is the reimbursement gap and the dilution math; the thing the bears refuse to see is that this is one of the very few neurorestoration assets with an actual FDA label and Nature-grade data today, not a slide deck. The real call isn't bull-vs-bear on the science — the science is good — it's whether you'll be diluted to death waiting for the business to catch up to the technology.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• Where revenue is concentrated: ~100% on one product (ARC-EX) in one geography (US) with no established reimbursement. Shift any one of those — a payer says no, a competitor predicates onto the De Novo, the US rehab channel saturates — and the revenue story stalls. This is maximal concentration risk.
• Why the moat is weaker than bulls think: the De Novo classification, once granted, can become a predicate that lets fast-followers in via 510(k) — ONWARD may have opened the category for Medtronic/Abbott/Boston Scientific (who own the surgical SCS channel) rather than fenced it off. The science moat lives in two founders and one Swiss lab — a key-person risk as much as an asset.
• Most dangerous competitor bulls underestimate: not Neuralink (different, earlier) — it's the implanted-SCS incumbents (Medtronic et al.) who could bolt an SCI functional-recovery indication onto an existing surgical franchise with vastly more salesforce and payer leverage, and the reimbursement status quo itself (no code = no scale).
• Worst capital-allocation reality: serial, accelerating dilution. Equity raises in Oct-2025 (€50.9M) and Apr-2026 (€40M+) at a depressed price, with runway still only to ~Q1 2028 and the key product launch (ARC-IM) beyond that horizon. Every milestone is funded by selling more stock low.
• What must hold for today's ~€2.8 price: essentially that ARC-EX keeps ramping and that the ARC-IM optionality doesn't go to zero. For the €9.50 target to hold, you need reimbursement and a successful Empower BP and tolerable dilution — a three-part conjunction.
• If growth disappoints 20–30%: at this stage revenue misses matter less than the next interim readout and the next raise — a soft ARC-EX year mostly just shortens runway and worsens dilution terms. The asymmetric risk is binary (Empower BP) and structural (dilution), not incremental.
• Single scenario that permanently impairs the business: Empower BP interim fails AND CMS declines ARC-EX coverage. In that world ONWARD is a sub-€15M-revenue company with a moonshot BCI program and no cash runway to reach it — a recap-or-bust outcome. Plausibility: moderate — each leg is independently ~30–50% likely, so the joint catastrophic case is maybe ~15–20% ``, which is non-trivial for a name the Street rates Strong Buy.

Lens 14 · Management Questions (15, ordered by information value)

1. Reimbursement is the gating variable and your IR materials barely mention it — what is the concrete US (CMS/commercial) and EU coverage pathway and timeline for ARC-EX, and what coverage assumption underlies your revenue plans?
2. At ~€58M annual burn and runway to ~Q1 2028, but guided ARC-IM commercialisation in H2 2028 — how many more equity raises do you expect before profitability, and how are you protecting shareholders from dilution at depressed prices?
3. What is the Empower BP interim (early 2027) success definition — the specific endpoint, effect size, and statistical bar — and what is your honest internal PoS?
4. ARC-EX ASP appears to differ between FY2025 (€32k/system) and Q1-2026 (€19k/system) — is realised price falling, or is this a mix shift to home units / consumables? Walk us through ARC-EX unit economics at scale.
5. Your De Novo classification can become a 510(k) predicate for followers — what stops Medtronic/Abbott/Boston Scientific from adding an SCI functional-recovery indication and out-distributing you?
6. What is the gross-to-net and recurring-consumable revenue per installed ARC-EX system over its life — i.e. what does the razor-and-blade actually look like?
7. How dependent is the entire pipeline on the.NeuroRestore lab and on Profs. Courtine and Bloch personally — what is the key-person mitigation and the IP-ownership split between ONWARD and EPFL?
8. What are the specific patent families and expiry dates protecting ARC-EX and the BCI-paired stimulation, and where is the estate weakest?
9. Where does Ottobock fit strategically beyond being your largest shareholder — is there (or will there be) a binding global distribution agreement, and on what economics?
10. What is the realistic peak-sales and pricing model for ARC-IM in hemodynamic instability, and how confident are you in payer willingness to fund an implant for blood-pressure regulation?
11. How big and how reachable is the truly addressable chronic-incomplete-tetraplegia population for ARC-EX in the US and EU, net of clinical eligibility?
12. The ARC-BCI program drives a lot of the narrative — how much capital are you willing to spend on it pre-revenue, and at what point would you partner or spin it out rather than fund it from dilutive equity?
13. What manufacturing/CDMO partners build ARC-EX and the ARC-IM implant, and where are the supply single-points-of-failure as you scale?
14. What does the path to cash-flow breakeven look like under your base case — revenue level, year, and the key assumptions — and what would have to go right to pull it forward?
15. If you had to cut spend to extend runway without a raise, what gets cut first — and what does that tell us about which programs you'd defend to the end?

---